von Wyl, V;
Cambiano, V;
Jordan, MR;
Bertagnolio, S;
Miners, A;
Pillay, D;
Lundgren, J;
(2012)
Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring.
PLoS One
, 7
(8)
, Article e42834. 10.1371/journal.pone.0042834.
![[thumbnail of 1376958.pdf]](https://discovery.ucl.ac.uk/style/images/fileicons/application_pdf.png) Preview |
PDF
1376958.pdf Download (473kB) |
Abstract
The most recent World Health Organization (WHO) antiretroviral treatment guidelines recommend the inclusion of zidovudine (ZDV) or tenofovir (TDF) in first-line therapy. We conducted a cost-effectiveness analysis with emphasis on emerging patterns of drug resistance upon treatment failure and their impact on second-line therapy.
| Type: | Article |
|---|---|
| Title: | Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring. |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1371/journal.pone.0042834 |
| Publisher version: | http://dx.doi.org/10.1371/journal.pone.0042834 |
| Language: | English |
| Additional information: | © von Wyl et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. The research leading to these results has received partial funding from the European Community’s Seventh Framework Programme (FP7/2007–2013) under the project ‘Collaborative HIV and Anti-HIV Drug Resistance Network (CHAIN)’ – grant agreement n° 223131. VvW was supported by a Swiss National Science Foundation (SNF) Grant for Prospective Researchers (PBEZP3-125726), and MRJ has received a grant from the National Institutes of Health (NIH K23 AI074423-05). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. |
| Keywords: | Adenine, Adult, Africa South of the Sahara, Anti-Retroviral Agents, Cost-Benefit Analysis, Drug Resistance, Viral, Epidemics, Female, Genotype, HIV Infections, HIV-1, Humans, Male, Middle Aged, Organophosphonates, Stochastic Processes, Treatment Outcome, Zidovudine |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Infection and Immunity UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health > Infection and Population Health |
| URI: | https://discovery.ucl.ac.uk/id/eprint/1376958 |
Archive Staff Only
 |
View Item |
